Current I.B.D (Inflammatory Bowel Disease) Studies


Sponsor: Centocor
Protocol Number: C0168T62
Title: "A Multicenter International Study of the Long-Term Safety of Infliximab
(REMICADE) in Ulcerative Colitis; RESUTLS UC: REMICADE Safety Under Long
Term Study in Ulcerative Colitis
(not recruiting)

Current Liver Studies

Sponsor: Bristol-Myers Squibb
Protocol Number : A1463-080
Title : Randomized, Observational Study of Entecavir to Assess Long-term Outcomes'
Associated with NucleosidelNucleotide Monotherapy for Patients with Chronic 1-BVI
Infection: The REALM Study
(not recruiting)

Sponsor: unspecified
Protocol Number: ######
Title: A phase III, randomised, double-blind and placebo-controlled study of once daily Investigational Study Drug 120 mg for 24 weeks and Investigational Study Drug 240 mg for 12 weeks in combination with pegylated interferon-α and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection
(recruiting)


Sponsor: F. Hoffmann-La Roche Ltd.
Protocol Number : NV22621
Title: A Randomized, Double-blinded, Multicenter Study to Evaluate the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® for 24 weeks versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus
Infection
(not recruiting)

Sponsor: F. Hoffmnann-La Roche Ltd.
Protocol Number: NV22688
Title: A long-term monitoring study to evaluate the persistence of direct acting antiviral
(DAA) treatment-resistant mutations or the durability of sustained virological response
(SVR) in patients treated with DAA-eontaining regimens for chronic hepatitis C infection
(CHC)
(not recruiting)

Sponsor: Gilead
Protocol Number : GS-US-174-0102
Title: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B
(not recruiting)

Sponsor: Gilead
Protocol Number: GS-US-203-0101
Title: A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DE)
Monotherapy Versus the Combination of Emtricitabine and Tenofovir DE for the Treatment of Chronic Hepatitis B
(not recruiting)

Sponsor: Gilead
Protocol Number : GS-US-174-0121
Title: A Phase 3b, Randomized, Double-Blind, Double Dummy Study Evaluating the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are Resistant to Lamivudine
(not recruiting)

Protocol Number: Geno 3 Demographics Study
Title: Demography, Clinical Characteristics, Metabolic Status, Viral Subtype and Genetics of Infection with Hepatitis C Genotype 3 in Canada
(recruiting)

Protocol Number: P05063
Title: Long-Term Follow-Up of Subjects in a Phase 1, 2 or 3 Clinical Trial in which Study Drug was Administered for the Treatment of Chronic Hepatitis C
(not recruiting)

Protocol Number: P05514
Title: A Single-Arm Study to Provide Study Drug Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Study Drug Studies
(not recruiting)

Sponsor: ZymoGenetics, Inc.
Protocol Number: 526H04
Title: Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naïve Subjects with Chronic Hepatitis C Virus Infection
(not recruiting)


Current Other Studies

Sponsor: AMAG-Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01114139
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia
(not recruiting)

Sponsor: AMAG-Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01114217
Title: A Phase III, Open –Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia.
 (not recruiting)